Nilotinib for First-line Newly Diagnosed CML-CP Patients

NCT03942094 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia, Chronic Phase
Nilotinib

Interventions

DRUG: Nilotinib

Sponsor

Shenzhen Second People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]